Human leukocyte antigen variants associate with BNT162b2 mRNA vaccine response.


Journal

Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676

Informations de publication

Date de publication:
04 Apr 2024
Historique:
received: 05 07 2023
accepted: 21 03 2024
medline: 5 4 2024
pubmed: 5 4 2024
entrez: 4 4 2024
Statut: epublish

Résumé

Since the beginning of the anti-COVID-19 vaccination campaign, it has become evident that vaccinated subjects exhibit considerable inter-individual variability in the response to the vaccine that could be partly explained by host genetic factors. A recent study reported that the immune response elicited by the Oxford-AstraZeneca vaccine in individuals from the United Kingdom was influenced by a specific allele of the human leukocyte antigen gene HLA-DQB1. We carried out a genome-wide association study to investigate the genetic determinants of the antibody response to the Pfizer-BioNTech vaccine in an Italian cohort of 1351 subjects recruited in three centers. Linear regressions between normalized antibody levels and genotypes of more than 7 million variants was performed, using sex, age, centers, days between vaccination boost and serological test, and five principal components as covariates. We also analyzed the association between normalized antibody levels and 204 HLA alleles, with the same covariates as above. Our study confirms the involvement of the HLA locus and shows significant associations with variants in HLA-A, HLA-DQA1, and HLA-DQB1 genes. In particular, the HLA-A*03:01 allele is the most significantly associated with serum levels of anti-SARS-CoV-2 antibodies. Other alleles, from both major histocompatibility complex class I and II are significantly associated with antibody levels. These results support the hypothesis that HLA genes modulate the response to Pfizer-BioNTech vaccine and highlight the need for genetic studies in diverse populations and for functional studies aimed to elucidate the relationship between HLA-A*03:01 and CD8+ cell response upon Pfizer-BioNTech vaccination. It is known that people respond differently to vaccines. It has been proposed that differences in their genes might play a role. We studied the individual genetic makeup of 1351 people from Italy to see if there was a link between their genes and how well they responded to the BNT162b2 mRNA COVID-19 vaccine. We discovered certain genetic differences linked to higher levels of protection in those who got the vaccine. Our findings suggest that individual’s genetic characteristics play a role in vaccine response. A larger population involving diverse ethnic backgrounds will need to be studied to confirm the generalizability of these findings. Better understanding of this could facilitate improved vaccine designs against new SARS-CoV-2 variants.

Sections du résumé

BACKGROUND BACKGROUND
Since the beginning of the anti-COVID-19 vaccination campaign, it has become evident that vaccinated subjects exhibit considerable inter-individual variability in the response to the vaccine that could be partly explained by host genetic factors. A recent study reported that the immune response elicited by the Oxford-AstraZeneca vaccine in individuals from the United Kingdom was influenced by a specific allele of the human leukocyte antigen gene HLA-DQB1.
METHODS METHODS
We carried out a genome-wide association study to investigate the genetic determinants of the antibody response to the Pfizer-BioNTech vaccine in an Italian cohort of 1351 subjects recruited in three centers. Linear regressions between normalized antibody levels and genotypes of more than 7 million variants was performed, using sex, age, centers, days between vaccination boost and serological test, and five principal components as covariates. We also analyzed the association between normalized antibody levels and 204 HLA alleles, with the same covariates as above.
RESULTS RESULTS
Our study confirms the involvement of the HLA locus and shows significant associations with variants in HLA-A, HLA-DQA1, and HLA-DQB1 genes. In particular, the HLA-A*03:01 allele is the most significantly associated with serum levels of anti-SARS-CoV-2 antibodies. Other alleles, from both major histocompatibility complex class I and II are significantly associated with antibody levels.
CONCLUSIONS CONCLUSIONS
These results support the hypothesis that HLA genes modulate the response to Pfizer-BioNTech vaccine and highlight the need for genetic studies in diverse populations and for functional studies aimed to elucidate the relationship between HLA-A*03:01 and CD8+ cell response upon Pfizer-BioNTech vaccination.
It is known that people respond differently to vaccines. It has been proposed that differences in their genes might play a role. We studied the individual genetic makeup of 1351 people from Italy to see if there was a link between their genes and how well they responded to the BNT162b2 mRNA COVID-19 vaccine. We discovered certain genetic differences linked to higher levels of protection in those who got the vaccine. Our findings suggest that individual’s genetic characteristics play a role in vaccine response. A larger population involving diverse ethnic backgrounds will need to be studied to confirm the generalizability of these findings. Better understanding of this could facilitate improved vaccine designs against new SARS-CoV-2 variants.

Autres résumés

Type: plain-language-summary (eng)
It is known that people respond differently to vaccines. It has been proposed that differences in their genes might play a role. We studied the individual genetic makeup of 1351 people from Italy to see if there was a link between their genes and how well they responded to the BNT162b2 mRNA COVID-19 vaccine. We discovered certain genetic differences linked to higher levels of protection in those who got the vaccine. Our findings suggest that individual’s genetic characteristics play a role in vaccine response. A larger population involving diverse ethnic backgrounds will need to be studied to confirm the generalizability of these findings. Better understanding of this could facilitate improved vaccine designs against new SARS-CoV-2 variants.

Identifiants

pubmed: 38575714
doi: 10.1038/s43856-024-00490-2
pii: 10.1038/s43856-024-00490-2
doi:

Types de publication

Journal Article

Langues

eng

Pagination

63

Informations de copyright

© 2024. The Author(s).

Références

Wei, J. et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat. Microbiol. 6, 1140–1149 (2021).
doi: 10.1038/s41564-021-00947-3 pubmed: 34290390 pmcid: 8294260
Newport, M. J. et al. Genetic regulation of immune responses to vaccines in early life. Genes Immun. 5, 122–129 (2004).
doi: 10.1038/sj.gene.6364051 pubmed: 14737096
Mentzer, A. J. et al. Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nat. Med. 29, 147–157 (2023).
doi: 10.1038/s41591-022-02078-6 pubmed: 36228659
Harris, P. A. et al. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed. Inform. 42, 377–381 (2009).
doi: 10.1016/j.jbi.2008.08.010 pubmed: 18929686
Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
doi: 10.1086/519795 pubmed: 17701901 pmcid: 1950838
Fuchsberger, C., Abecasis, G. R. & Hinds, D. A. minimac2: faster genotype imputation. Bioinformatics 31, 782–784 (2015).
doi: 10.1093/bioinformatics/btu704 pubmed: 25338720
Loh, P. R. et al. Reference-based phasing using the Haplotype Reference Consortium panel. Nat. Genet. 48, 1443–1448 (2016).
doi: 10.1038/ng.3679 pubmed: 27694958 pmcid: 5096458
Das, S. et al. Next-generation genotype imputation service and methods. Nat. Genet. 48, 1284–1287 (2016).
doi: 10.1038/ng.3656 pubmed: 27571263 pmcid: 5157836
McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet 48, 1279–1283 (2016).
doi: 10.1038/ng.3643 pubmed: 27548312 pmcid: 5388176
Verlouw, J. A. M. et al. A comparison of genotyping arrays. Eur. J. Hum. Genet. 29, 1611–1624 (2021).
doi: 10.1038/s41431-021-00917-7 pubmed: 34140649 pmcid: 8560858
Luo, Y. et al. A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response. Nat. Genet. 53, 1504–1516 (2021).
doi: 10.1038/s41588-021-00935-7 pubmed: 34611364 pmcid: 8959399
Yang, J. et al. FTO genotype is associated with phenotypic variability of body mass index. Nature 490, 267–272 (2012).
doi: 10.1038/nature11401 pubmed: 22982992 pmcid: 3564953
Sakaue, S. et al. Tutorial: a statistical genetics guide to identifying HLA alleles driving complex disease. Nat. Protoc. 18, 2625–2641. (2023).
Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. Roy. Stat. Soc.: Series B (Methodological) 57, 289–300 (1995).
Augusto, D. G. & Hollenbach, J. A. HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection. Curr. Opin. Immunol. 76, 102178 (2022).
doi: 10.1016/j.coi.2022.102178 pubmed: 35462277 pmcid: 8947957
Wolday, D. et al. HLA Variation and SARS-CoV-2 Specific Antibody Response. Viruses 15, 906 (2023).
doi: 10.3390/v15040906 pubmed: 37112884 pmcid: 10143129
Oberhardt, V. et al. Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. Nature 597, 268–273 (2021).
doi: 10.1038/s41586-021-03841-4 pubmed: 34320609 pmcid: 8426185
Valentine, K. M. et al. CD8 Follicular T Cells Promote B Cell Antibody Class Switch in Autoimmune Disease. J. Immunol. 201, 31–40 (2018).
doi: 10.4049/jimmunol.1701079 pubmed: 29743314
Chen, M., Venturi, V. & Munier, C. M. L. Dissecting the Protective Effect of CD8+ T Cells in Response to SARS-CoV-2 mRNA Vaccination and the Potential Link with Lymph Node CD8+ T Cells. Biology (Basel) 12, 1035 (2023).
doi: 10.3390/genes14051035 pubmed: 37508464
Tyllis, T. S. et al. CXCR5+CD8+ T Cells Shape Antibody Responses In Vivo Following Protein Immunisation and Peripheral Viral Infection. Front. Immunol. 12, 626199 (2021).
doi: 10.3389/fimmu.2021.626199 pubmed: 34326833 pmcid: 8314013
Bolze, A. et al. HLA-A*03:01 is associated with increased risk of fever, chills, and stronger side effects from Pfizer-BioNTech COVID-19 vaccination. Hum. Genet. Genomics Adv. 3, 100084 (2022).
doi: 10.1016/j.xhgg.2021.100084
Rendine, S. et al. Estimation of human leukocyte antigen class I and class II high-resolution allele and haplotype frequencies in the Italian population and comparison with other European populations. Hum. Immunol. 73, 399–404 (2012).
doi: 10.1016/j.humimm.2012.01.005 pubmed: 22342872

Auteurs

Martina Esposito (M)

National Research Council, Institute for Biomedical Technologies, Segrate, MI, Italy.

Francesca Minnai (F)

National Research Council, Institute for Biomedical Technologies, Segrate, MI, Italy.
Department of Medical Biotechnology and Translational Medicine (BioMeTra), Università degli Studi di Milano, Milan, Italy.

Massimiliano Copetti (M)

Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.

Giuseppe Miscio (G)

Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.

Rita Perna (R)

Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.

Ada Piepoli (A)

Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.

Gabriella De Vincentis (G)

Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.

Mario Benvenuto (M)

Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.

Paola D'Addetta (P)

Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.

Susanna Croci (S)

Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Medical Genetics, University of Siena, Siena, Italy.

Margherita Baldassarri (M)

Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Medical Genetics, University of Siena, Siena, Italy.

Mirella Bruttini (M)

Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Medical Genetics, University of Siena, Siena, Italy.
Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Siena, Italy.

Chiara Fallerini (C)

Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Medical Genetics, University of Siena, Siena, Italy.

Raffaella Brugnoni (R)

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Paola Cavalcante (P)

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Fulvio Baggi (F)

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Elena Maria Grazia Corsini (EMG)

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Emilio Ciusani (E)

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Francesca Andreetta (F)

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Tommaso A Dragani (TA)

Aspidia srl, Milan, Italy.

Maddalena Fratelli (M)

Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milan, Italy.

Massimo Carella (M)

Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy.

Renato E Mantegazza (RE)

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Alessandra Renieri (A)

Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Medical Genetics, University of Siena, Siena, Italy.
Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Siena, Italy.

Francesca Colombo (F)

National Research Council, Institute for Biomedical Technologies, Segrate, MI, Italy. francesca.colombo@cnr.it.

Classifications MeSH